Bristol-Myers Squibb Co. (BMY)
What changed in recent filings
- Institutions — 7 new · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Bristol-Myers Squibb Co.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 8 → 2026 Q2: 8 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Bristol-Myers Squibb Co.
Institutions we track that reported holding this stock in their most recent 13F.
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- National Pension Service (Korea)0.21% of portfolio · held as of 2026 Q2 or earlier
- Pzena Investment Management2.88% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.35% of portfolio · held as of 2026 Q2 or earlier
- GQG Partners0.01% of portfolio · held as of 2026 Q2 or earlier
- Capital World Investors0.02% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management0.85% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Bristol-Myers Squibb Co. is classified under the Biotech & Health sector. See peers below.
BMY segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
ETFs holding Bristol-Myers Squibb Co.
Per SEC N-PORT · 2026-05-31 · by weight · factual
BMY on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BMY FAQ
What is Bristol-Myers Squibb Co. (BMY)?
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
What sector is Bristol-Myers Squibb Co. in?
Bristol-Myers Squibb Co. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze Bristol-Myers Squibb Co. (BMY) stock?
On Stocklore you can see BMY's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.